Future Neurology , January 2013, Vol. 8, No. 1, Pages 13-16. more
To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Aim: To optimize warfarin dose in patients at risk for thrombotic events, we have recently developed a pharmacogenomic algorithm, which explained 44.9% of the variability in warfarin dose requirements using age, gender, BMI, vitamin K intake, CYP2C9 (*2 and *3) and VKORC1 (*3, *4 and -1639 G>A) as predictors. The aim of the current study is to develop an expanded genetic model that can explain greater percentage of warfarin variability and that has clinical validity. Patients & methods: CYP2C9*8, CYP4F2 V433M, GGCX G8016A and thyroid status were added to an expanded genetic model (n = 243). Results: The expanded genetic model explained 61% of the variability in warfarin dose requirements, has a prediction accuracy of ±11 mg/week and can differentiate warfarin sensitive and warfarin resistant groups efficiently (areas under receiver operating characteristic curves: 0.93 and 0.998, respectively; p < 0.0001). Higher percentage of International Normalized Ratios in therapeutic range (52.68 ± 4.21 vs 43.80 ± 2...
|Authors:||Addepalli Pavani; Shaik Mohammad Naushad; Ramesh C Mishra; Amaresh Rao Malempati; Ramakrishna Pinjala; Takallapally Ramesh Kumar; Vijay Kumar Kutala|
This is where you can add this publication to your personal favourites.
Future Neurology , January 2013, Vol. 8, No. 1, Pages 5-7. more
Future Neurology , January 2013, Vol. 8, No. 1, Pages 1-3. more